Nebivolol Sandoz Ltd (Nebivolol)

Nebivolol is a selective β1‑adrenergic antagonist used in the management of cardiovascular conditions that involve elevated vascular resistance.

• Hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension.
• Heart failure with reduced ejection fraction: improves cardiac output and may reduce hospitalization risk.
• Left ventricular dysfunction: supports ventricular remodeling by lowering afterload.

• Nebivolol binds selectively to β1‑adrenergic receptors on cardiac myocytes, inhibiting catecholamine‑induced stimulation and decreasing heart rate and contractility. Concurrently, it stimulates endothelial nitric‑oxide synthase, increasing nitric‑oxide production, which causes vasodilation and reduces peripheral vascular resistance, contributing to its antihypertensive effect.

Nebivolol may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity.
• Dizziness or light‑headedness, especially after standing.
• Fatigue or general tiredness.
• Nausea or mild gastrointestinal upset.
• Bradycardia: slower than normal heart rate.
• Insomnia or sleep disturbances.

Serious or Rare Side Effects

• Severe bradycardia or heart block requiring medical attention.
• Marked hypotension leading to fainting.
• Allergic reactions such as rash, pruritus, or angioedema.
• Hepatic dysfunction or elevated liver enzymes.
• Worsening heart failure symptoms.
• Bronchospasm in patients with reactive airway disease.

Before initiating Nebivolol therapy, clinicians should consider several safety aspects.

• Blood pressure monitoring: ensure adequate control and avoid excessive drops.
• Cardiac assessment: evaluate heart rate and conduction abnormalities.
• Asthma or chronic obstructive pulmonary disease: use with caution due to potential bronchoconstriction.
• Abrupt discontinuation: taper gradually to prevent rebound hypertension.
• Renal impairment: dose adjustment may be required in severe dysfunction.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Combined use with other beta‑blockers: may cause excessive bradycardia or hypotension.
• Calcium‑channel blockers verapamil or diltiazem: increase plasma levels and risk of cardiac depression.
• Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): raise Nebivolol concentrations, enhancing adverse effects.

Moderate Interactions (Monitor Closely):\n- NSAIDs: may blunt antihypertensive response.

• Diuretics: can potentiate hypotensive effects.
• ACE inhibitors or ARBs: monitor for additive blood pressure lowering.
• Antiarrhythmic agents (e.g., amiodarone): watch for conduction disturbances.
• Antidiabetic drugs: monitor glucose control as blood pressure changes may affect glycemia.